<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1609">
  <stage>Registered</stage>
  <submitdate>28/06/2007</submitdate>
  <approvaldate>28/06/2007</approvaldate>
  <nctid>NCT00495196</nctid>
  <trial_identification>
    <studytitle>Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration</studytitle>
    <scientifictitle>Cardiovascular Response to Peripheral Chemoreceptor Stimulation in Congestive Heart Failure With Cheyne- Stokes Respiration</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>X07-0079</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure, Congestive</healthcondition>
    <healthcondition>Cheyne-Stokes Respiration</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Experimental lung function test

Experimental: 1 - 

Active Comparator: 2 - 


Treatment: surgery: Experimental lung function test
Administration of several CO2 gas mixtures

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cardiovascular parameters such as continuous blood pressure and heart rate.</outcome>
      <timepoint>During administration of the intervention</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Moderate to severe heart failure (NYHA Class II or above) on optimal medical therapy

          -  LVEF less than or equal to 45%

          -  Stable condition as defined as no hospital admission or changes to medical therapy
             within two weeks prior to enrolment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Patients taking known respiratory stimulants or depressants

          -  Clinically significant asthma requiring therapy

          -  Significant parenchymal lung disease

          -  Primary pulmonary hypertension

          -  Myocardial infarction within three months prior to enrolment

          -  Patients with cardiac resynchronisation devices and permanent pacemakers

          -  Anaemic (haemoglobin &lt; 12g/dL)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ResMed</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the trial is to investigate the cardiovascular response to peripheral
      chemoreceptor stimulation in Congestive Heart Failure with Cheyne- Stokes Respiration</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00495196</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rachel A Coxon, BE/MBiomedE</name>
      <address>ResMed/The University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>